It’s been a rollercoaster ride for health insurers, the elderly and medical providers who participate in the US government’s Medicare Advantage program. A $13 billion bump in 2027 payments is just the start. https://t.co/HeCfbpLrAF ...

Core Insights - Clover Health (CLOV) is positioned uniquely within the Medicare Advantage market, with recent developments challenging prevailing skepticism about its performance [1] Company Analysis - Clover Health has been under scrutiny, yet recent data suggests that doubts regarding its viability may be unfounded [1] - The company aims to provide a clear and honest perspective on its operations, focusing on what is effective and identifying potential opportunities [1]

A congressional committee found that controversial practices like adding diagnoses in Medicare Advantage triggered higher bills for America’s seniors. https://t.co/4btcrlgpNm ...

The average American senior’s Medicare premiums last year were about 10% higher, or more than $200 annually, because of alleged overpayments to private Medicare Advantage plans, congressional investigators found. 🔗 https://t.co/dvxkb4ToY8 https://t.co/6N8HK3vgRi ...

Core Insights - Heather Cianfrocco, a key executive at UnitedHealth, is leaving the company after 24 years, having held various leadership roles including CEO of Optum and executive vice president of governance, compliance, and information security [2][3] Company Changes - Cianfrocco's departure follows a challenging period for UnitedHealth, marked by declining profits and rising expenses in its insurance division, particularly in Medicare Advantage [4] - The company has seen a 9% reduction in Medicare Advantage beneficiaries compared to the previous year, as it attempts to mitigate the impact of unfavorable regulatory changes [5] Financial Performance - UnitedHealth reported its lowest annual profit since 2018 and anticipates a revenue contraction for the first time in decades [5] - The Centers for Medicare & Medicaid Services (CMS) proposed a flat Medicare Advantage rate update for the upcoming year, which could further impact profitability for MA insurers [6] Regulatory Environment - The Trump administration has focused on reducing overpayments in the privatized Medicare program, with proposed rules that could limit risk adjustment strategies used by insurers [7] - The CMS plans to conduct accelerated audits of Medicare Advantage plans, which may pose additional challenges for the industry [7]

Core Insights - Clover Health Investments, Corp. (CLOV) reported an adjusted fourth-quarter 2025 loss per share of 5 cents, compared to an adjusted earnings per share of 2 cents in the same period last year, aligning with the Zacks Consensus Estimate [1] - The company experienced a GAAP loss of 10 cents per share from continuing operations, an increase from a 4-cent loss in the prior year [1] Financial Performance - For 2025, Clover Health reported a loss per share of 17 cents, which is higher than the 9 cents loss from the previous year. Adjusted EPS for 2025 was 4 cents, down from 14 cents in the prior year [2] - Total revenues for Q4 reached $487.7 million, marking a 44.7% year-over-year increase and surpassing the Zacks Consensus Estimate by 3.2% [3] - For the full year 2025, total revenues amounted to $1.92 billion, reflecting a 40.3% increase compared to 2024 [3] Segment Analysis - Clover Health's revenues are derived from two main segments: Insurance and Other income. Insurance revenues in Q4 totaled $485.9 million, up 46.9% year-over-year, driven by a 38% increase in Medicare Advantage membership and strong member retention [4] - The Insurance Benefit Expense Ratio (BER) for CLOV was 95%, a modest increase from 82.8% in the previous year, attributed to new member dilution and quality investments [5] - Other income decreased to $1.8 million, down 71% from the prior year [5] Operational Metrics - Net medical claims rose 70.1% year-over-year to $413.5 million in Q4, while salaries and benefits expenses decreased by 9.2% to $56.9 million. General and administrative expenses increased by 26.5% to $66.2 million, leading to total operating expenses of $537 million, a 49.8% increase year-over-year [6] - The total operating loss for the quarter was $49.3 million, compared to an operating loss of $21.4 million in the same quarter last year [6] Cash Position - At the end of Q4 2025, Clover Health had cash and cash equivalents of $78.3 million, down from $190.1 million at the end of Q3 2025 [7] Future Guidance - For 2026, Clover Health projects total revenues between $2.81 billion and $2.92 billion, indicating a potential 49% year-over-year growth at the midpoint. The Zacks Consensus Estimate stands at $2.62 billion [10] - The company anticipates GAAP net income to be in the range of $0-$20 million, with average Medicare Advantage membership expected to be between 154,000 and 158,000, reflecting a 46% year-over-year growth at the midpoint [10] Market Performance - Following the announcement of better-than-expected revenue guidance for 2026, CLOV shares gained 2.3% in after-hours trading. Over the past six months, CLOV shares have declined by 20.1%, while the industry has seen a decline of 37.2% [12] - The company has demonstrated its ability to maintain profitability amid industry challenges, achieving full-year adjusted EBITDA profitability and a 38% year-over-year growth in Medicare Advantage membership [13]

Financial Data and Key Metrics Changes - In 2025, Clover Health achieved full year Adjusted EBITDA profitability, with total revenue increasing by 40% year-over-year to $1.9 billion [20][21] - Insurance revenue in Q4 was $486 million, a 47% increase year-over-year, while for the full year, it was $1.9 billion, reflecting a 41% increase [20][21] - Consolidated Gross Profit for 2025 was $356 million, and the insurance segment BER was 90.9%, an increase of 970 basis points year-over-year [22][23] Business Line Data and Key Metrics Changes - Medicare Advantage membership grew by 38% year-over-year to approximately 114,000 members at year-end [20] - New member contribution loss improved to $145 per member per month (PNPM), while returning member contribution profit remained strong at $200 PNPM year-over-year [19] Market Data and Key Metrics Changes - Clover Health experienced a 53% year-over-year membership growth during the 2026 annual enrollment period, driven by a stable benefit offering and strong retention [9] - The company maintained a well-controlled medical cost trend at 5% year-over-year, despite industry-wide cost pressures [18][21] Company Strategy and Development Direction - Clover Health aims to achieve its first full year of GAAP net income profitability in 2026, supported by strong member retention and a stable benefit design [10][26] - The company emphasizes the importance of clinical value and disciplined cost management over coding intensity, positioning itself favorably against competitors [5][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's trajectory, highlighting that regulatory actions affecting the Medicare Advantage industry create competitive advantages for Clover [5][11] - The company anticipates continued growth and profitability, driven by the maturation of new members and the deepening engagement with Clover Assistant [10][30] Other Important Information - Clover Health's strategy includes expanding the Counterpart platform to manage a significant number of members, similar to those under Clover Assistant [17][51] - The company plans to reduce Adjusted SG&A as a percentage of total revenue by approximately 100-150 basis points year-over-year [27] Q&A Session Summary Question: Gross profit margin decline despite improving cohort economics - Management acknowledged the decline in gross profit margin, attributing it to the dilution from new cohorts and emphasizing confidence in improving profitability as these cohorts mature [38][40] Question: Impact of risk model changes on growth rates - Management indicated that while the industry expected higher growth rates, they found the preliminary rates reasonable and emphasized the importance of improving data linking for risk adjustment [41][43] Question: Insights on new cohort performance - Management reported that the profitability of new members is in line with expectations, with utilization decreasing in early 2026 [50] Question: Contribution of Counterpart Health to 2026 guidance - Management stated that while Counterpart Health is progressing well, it is too early to quantify its economic impact on 2026 guidance [51][53] Question: Expectations for CA-empowered physician engagement with new cohort - Management anticipates some pressure on CA penetration due to growth but remains confident in maintaining historical engagement levels in core markets [55][56]

Financial Data and Key Metrics Changes - Health plan membership reached 236,300, reflecting a year-over-year growth of approximately 25% [5] - Total revenue for Q4 2025 was $1 billion, a 44% increase year-over-year, while full-year revenue was $3.9 billion, growing 46% year-over-year [5][16] - Adjusted gross profit for Q4 was $125 million, with an adjusted margin of 87.7%, and for the full year, adjusted gross profit was $495 million, with an MBR of 87.5%, improving by 130 basis points year-over-year [5][6] - Adjusted EBITDA for 2025 was $110 million, representing a margin of 2.8% and a 270 basis points expansion year-over-year [7][18] Business Line Data and Key Metrics Changes - The company demonstrated strong performance across all major cost categories, with inpatient admissions per thousand in the low 140s during Q4 [16] - The clinical model's operational advantages were highlighted, allowing for growth while expanding margins despite industry pressures [8] Market Data and Key Metrics Changes - Membership outside California grew significantly, with approximately 38,000 members representing 16% of total membership as of December 2025 [9] - The company achieved a 5-star plan rating in North Carolina for three consecutive years and maintained high ratings in other states [9] Company Strategy and Development Direction - The company aims to serve more seniors and is on a path towards 1 million members, focusing on quality care delivery [9] - Plans for 2026 include investing in sales and distribution, building relationships with broker partners, and expanding in markets outside California [10] - The company is committed to continuous improvement and targeted investments in clinical models and technology, including AI workflows [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving a 20% growth rate and emphasized the importance of maintaining a balance between growth and margin expansion [27] - The company is prepared for a potentially flat rate environment in 2027 and believes its model will continue to perform well regardless of rate changes [28][66] - Management highlighted the importance of a strong clinically led model and core medical cost management competencies to navigate future challenges [14] Other Important Information - The company generated positive free cash flow in 2025 and ended the year with $604 million in cash and investments [18] - A $200 million revolving credit facility was closed, indicating a mature capital structure [18] Q&A Session Summary Question: What would prevent Alignment from having a rerun of its past successes in 2027? - Management feels comfortable with a 20% growth rate and believes the model will work irrespective of rate changes, emphasizing disciplined growth and strong operational performance [27][28] Question: Can you elaborate on the assumptions embedded in the MLR for 2026? - Management indicated that the MLR improvement is about 10 basis points year-over-year, influenced by the new member mix and ongoing adjustments related to the V28 risk model [33][35] Question: How is the company planning to change its distribution network? - The company is focusing on deeper relationships with brokers and providers, with plans to enter new markets without being overly reliant on rate changes [40][41] Question: What is the company's exposure to the risk model rebasing component? - Management believes its exposure is limited compared to the industry due to its lower blended RAF scores and a focus on accurate coding and cost management [95][96] Question: How does the company view the potential changes in the Stars program? - Management considers the potential changes to be net neutral and believes simplification of the Stars program could be beneficial [85]

Financial Data and Key Metrics Changes - In 2025, the company achieved full year Adjusted EBITDA profitability, with total revenue increasing by 40% year-over-year to $1.9 billion [20][24] - Insurance revenue in Q4 2025 was $486 million, a 47% increase year-over-year [20] - The company reported a Consolidated Gross Profit of $356 million for the full year 2025, with a new member contribution loss improving to $145 per member per month (PNPM) [19][21] Business Line Data and Key Metrics Changes - Medicare Advantage membership grew by 38% year-over-year, reaching approximately 114,000 members by year-end [20] - The company maintained a well-controlled medical cost trend at 5% year-over-year, despite elevated utilization across the industry [18][20] - Adjusted SG&A as a percentage of total revenue improved to 17% for the full year, a 410 basis point improvement year-over-year [24] Market Data and Key Metrics Changes - The company experienced a 53% year-over-year membership growth during the 2026 annual enrollment period, driven by strong retention and a stable benefit offering [9][20] - The company is positioned as the largest individual non-special needs plan PPO in New Jersey, enhancing its attractiveness as a partner across the network [14] Company Strategy and Development Direction - The company aims to achieve its first full year of GAAP net income profitability in 2026, supported by strong member retention and a stable benefit design [10][28] - The strategy focuses on disciplined cost management and clinical integration, with an emphasis on improving care delivery and clinical outcomes [12][34] - The company plans to expand its Counterpart platform, aiming to manage as many members under Counterpart Assistant as under Clover Assistant [16][34] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to sustain profitability while growing membership, highlighting the structural advantages of its model [4][10] - The company anticipates favorable market dynamics and a four-star payment year in 2026, which will provide a financial tailwind [29] - Management noted that the broader Medicare Advantage policy direction aligns with the company's operational model, reinforcing its competitive positioning [11][13] Other Important Information - The company introduced Consolidated Gross Profit as a primary operating metric for guidance and reporting, replacing the insurance segment BER [21][22] - The company ended Q4 2025 with $320 million in cash and investments, maintaining a strong liquidity position [25] Q&A Session Summary Question: Concerns about gross profit margin decline - Management acknowledged the decline in gross profit margin, attributing it to the dilution from new cohorts and expressed confidence in improving profitability as these cohorts mature [39][41] Question: Impact of risk model changes on growth rates - Management indicated that the risk adjustment changes could improve interoperability but noted a potential oversight by CMS regarding data sharing for new members switching plans [42][44] Question: Insights on new cohort performance - Management reported that the profitability of new members is in line with expectations, with utilization decreasing in early 2026 [52] Question: Contribution of Counterpart Health to guidance - Management stated that while Counterpart Health is progressing well, it is too early to quantify its economic impact on guidance [53][55] Question: Expectations for CA-empowered physician engagement with new cohort - Management expects to maintain CA penetration rates in core markets despite growth pressures, aiming for increased engagement over time [58][59]

Group 1 - CVS Health Corp. reported sales of $105.69 billion, exceeding the consensus estimate of $103.59 billion [1] - Adjusted earnings were $1.09 per share, surpassing the analyst estimate of 99 cents, but decreased from $1.19 in the prior year [1] - The company reaffirmed its fiscal 2026 adjusted earnings guidance of $7.00-$7.20 per share, compared to the Street consensus of $7.17, indicating a strong position for 2026 [1] Group 2 - CVS updated its cash flow from operations guidance to at least $9.0 billion, down from at least $10.0 billion [2] - The company anticipates fiscal 2026 revenue of at least $400 billion, below the consensus of $409.77 billion, with adjusted operating income projected between $15.07 billion and $15.41 billion [2] Group 3 - Bank of America Securities views the reaffirmation of the 2026 guidance positively amid investor concerns regarding Medicare Advantage headwinds in 2027 and regulatory scrutiny in the pharmacy benefit manager sector [3] - In Health Care Benefits, group Medicare Advantage rate renewals are seen as opportunities to improve margins, supported by progress in Individual Medicare Advantage [4] - Analyst Allen Lutz noted that CVS has several strategies to counteract headwinds from the 2027 preliminary rate notice, including share repurchases and repricing of Group Medicare Advantage [4] Group 4 - In Health Services, Bank of America expects continued margin improvement in Oak Street due to clinic closures, fewer new openings, and growing patient panels, which support a path toward break-even [5] - Overall, Bank of America sees multiple levers in place to drive CVS's enterprise growth and maintains a positive outlook on the long-term strategy, reiterating a Buy rating with a price forecast of $95 [5] - CVS Health shares were up 0.87% at $76.36 at the time of publication [5]